Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas

Journal of Nuclear Medicine

Volumn 45, Issue 11, 2004, Pages 1838-1842

  Yamane, Tomohiko ^a   Daimaru, Osami ^a   Ito, Satoshi ^a   Yoshiya, Kazuhiko ^a   Nagata, Takeshi ^a   Ito, Shinichi ^a   Uchida, Hideo ^a  

^a Daiyukai General Hospital   (Japan)

Author keywords

18F FDG; Chemotherapy; Hematology; Malignant lymphoma; Oncology; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHODGKIN LYMPHOMA; PATIENT CODING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 16544372999     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. 18F-FDG scintigraphy. J Nucl Med. 1993;34:1706-1710.
2. 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1362.
3. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85:613-618.
4. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: comparison with CT. Leuk Lymphoma. 2000;39:543-553.
5. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
6. Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.
7. Yamane T, Daimaru O, Itoh S, et al. FDG-PET on the day after first chemotherapy in malignant lymphoma. Nippon Igaku Hoshasen Gakkai Zasshi. 2002;62:839-842.
8. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
9. 18F]FDG PET. Br J Cancer. 2002;86:506-511.
10. Cremerius U, Effert PJ, Adam G, et al. FDG-PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998;39:815-822.
11. 18F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30:682-688.
12. Haberkorn U, Altmann A, Kamencic H, et al. Glucose transport and apoptosis after gene therapy with thymidine kinase. Eur J Nucl Med. 2001;28:1690-1696.
13. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med. 2002;29:1462-1469.